Analysts are on the Bearish side about Circassia Pharmaceuticals Plc (LON:CIR) this week.

June 26, 2018 - By Michael Collier

Circassia Pharmaceuticals Plc (LON:CIR) LogoInvestors sentiment increased to 1.1 in Q1 2018. Its up 0.08, from 1.02 in 2017Q4. It is positive, as 10 investors sold Circassia Pharmaceuticals Plc shares while 32 reduced holdings. 12 funds opened positions while 34 raised stakes. 17.82 million shares or 5.33% more from 16.91 million shares in 2017Q4 were reported.
Alliancebernstein L P holds 0% of its portfolio in Circassia Pharmaceuticals Plc (LON:CIR) for 23,921 shares. Us Retail Bank De has invested 0% in Circassia Pharmaceuticals Plc (LON:CIR). Silvercrest Asset Group Inc Ltd Liability Co has 0.3% invested in Circassia Pharmaceuticals Plc (LON:CIR) for 716,368 shares. Morgan Stanley invested in 0% or 36,267 shares. Jennison Assocs invested in 0% or 9,075 shares. Ny State Common Retirement Fund has 0% invested in Circassia Pharmaceuticals Plc (LON:CIR) for 18,200 shares. American Int Incorporated reported 10,561 shares. Comerica Bankshares holds 0.01% or 17,199 shares. State Street holds 410,690 shares. Huntington Comml Bank reported 0% stake. Prospector Prtn Ltd Liability Corp invested 0.73% of its portfolio in Circassia Pharmaceuticals Plc (LON:CIR). Citadel Advsr Ltd Liability owns 68,974 shares for 0% of their portfolio. Fincl Bank Of Montreal Can owns 876 shares. Sector Pension Investment Board, Quebec – Canada-based fund reported 10,318 shares. Deutsche Natl Bank Ag stated it has 38,738 shares.

Circassia Pharmaceuticals Plc (LON:CIR) Ratings Coverage

Among 3 analysts covering Circassia Pharmaceuticals Plc (LON:CIR), 1 have Buy rating, 0 Sell and 2 Hold. Therefore 33% are positive. Circassia Pharmaceuticals Plc has GBX 140 highest and GBX 100 lowest target. GBX 120’s average target is 37.77% above currents GBX 87.1 stock price. Circassia Pharmaceuticals Plc had 11 analyst reports since January 4, 2018 according to SRatingsIntel. The rating was maintained by Peel Hunt with “Hold” on Thursday, February 1. The rating was maintained by Numis Securities on Tuesday, April 24 with “Buy”. The stock of Circassia Pharmaceuticals Plc (LON:CIR) has “Hold” rating given on Tuesday, April 24 by Peel Hunt. The stock has “Hold” rating by Peel Hunt on Tuesday, May 22. On Thursday, January 4 the stock rating was maintained by Peel Hunt with “Hold”. The firm earned “Hold” rating on Wednesday, April 4 by Peel Hunt. The firm has “Hold” rating by Peel Hunt given on Thursday, May 31. The firm has “Neutral” rating by JP Morgan given on Tuesday, April 24. On Tuesday, May 15 the stock rating was maintained by JP Morgan with “Neutral”. The stock of Circassia Pharmaceuticals Plc (LON:CIR) earned “Hold” rating by Peel Hunt on Wednesday, May 16. Below is a list of Circassia Pharmaceuticals Plc (LON:CIR) latest ratings and price target changes.

31/05/2018 Broker: Peel Hunt Rating: Hold Old Target: GBX 120.00 Maintain
22/05/2018 Broker: Peel Hunt Rating: Hold Old Target: GBX 120.00 Maintain
16/05/2018 Broker: Peel Hunt Rating: Hold Old Target: GBX 130.00 New Target: GBX 120.00 Maintain
15/05/2018 Broker: JP Morgan Rating: Neutral Old Target: GBX 125.00 New Target: GBX 100.00 Maintain
24/04/2018 Broker: JP Morgan Rating: Neutral Maintain
24/04/2018 Broker: Numis Securities Rating: Buy Old Target: GBX 180.00 New Target: GBX 140.00 Maintain
24/04/2018 Broker: Peel Hunt Rating: Hold New Target: GBX 130.00 Maintain
04/04/2018 Broker: Peel Hunt Rating: Hold Old Target: GBX 130.00 Maintain
01/03/2018 Broker: Peel Hunt Rating: Hold Old Target: GBX 130.00 New Target: GBX 130.00 Maintain
01/02/2018 Broker: Peel Hunt Rating: Hold Old Target: GBX 130.00 New Target: GBX 130.00 Maintain

The stock decreased 4.91% or GBX 4.5 during the last trading session, reaching GBX 87.1. About 1,731 shares traded. Circassia Pharmaceuticals Plc (LON:CIR) has 0.00% since June 26, 2017 and is . It has underperformed by 12.57% the S&P500.

Circassia Pharmaceuticals plc, a specialty biopharmaceutical company, focuses on the development and commercialization of products for the treatment of asthma and chronic obstructive pulmonary disease . The company has market cap of 290.45 million GBP. It markets novel NIOX asthma management products directly to specialists in the United States, the United Kingdom, and Germany, as well as through a network of partners internationally. It currently has negative earnings. The companyÂ’s asthma products comprise Fliveo that targets substitution of Flixotide, which has approved in the United Kingdom, as well as developing Seriveo that targets direct substitution of Seretide.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.